Project Grant R00HL161320
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$498K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Denver, CO 80206, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $692,768 to Rhode Island Hospital to study pulmonary arterial hypertension (PAH). The research aims to characterize endothelial cell dysfunction and anoikis resistance in PAH, using a novel "cell biopsy" method to harvest and analyze endothelial cells from pulmonary artery catheters. The project will define molecular mechanisms underlying PAH,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $244,589 to support research on the role of the protein VPS34 in the development and progression of pulmonary arterial hypertension (PAH). The primary research aims are to: 1) examine the regulation and activation of VPS34 in the pulmonary vasculature of PAH patients, 2) determine the impact of VPS34 on the proliferation and...
This federal Project Grant award, valued at $596,809.00 and issued by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to understand the role of the mitochondrial protein MitoNEET in the development and progression of pulmonary hypertension (PH), particularly in patients with PH secondary to lung disease (Group 3 PH). The key objectives are to define how MitoNEET regulates pulmonary artery smooth muscle cell...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $167,940 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Children's Hospital Corporation (doing business as Boston Children's Hospital) with a project period from Sep 20, 2024 to Aug 31, 2029. The grant aims to develop a novel mouse model of flow-induced pulmonary hypertension (PH) that better represents the physiological conditions observed in patients with congenital heart disease. Additionally, the project...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $602,955 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to National Jewish Health in Denver, Colorado. The 5-year grant, running from July 2024 to June 2029, will fund research to identify the unique functions and molecular drivers of airspace macrophage subsets during the resolution of lung inflammation and active lung repair. The primary objectives are to: 1) Test the hypothesis that a subset of airspace...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $605,678.00 to the University of South Alabama to conduct research on a novel mechanism regulating genome-wide mRNA expression in hypoxic lung disease. The research aims to explore the concept that a pathway called "BRACR" (Base Oxidation and Repair Activated Chromatin Restructuring) is a fundamental component of the...
The National Heart Lung and Blood Institute (NHLBI) awarded a $164,700 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to study the role of mTOR hyperactivation in pulmonary vascular remodeling. The research aims to examine how mTOR activation in specific mesenchymal cell populations alters endothelial cell behavior and function, and how aberrant mTOR...
This $498,000 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research at the University of Florida to investigate the role of microglia and neuroinflammation in the pathophysiology of pulmonary hypertension. The central hypothesis is that activation of resident microglia, especially the TREM2+ subtype, promotes aberrant preautonomic neuronal signaling in the paraventricular...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $122,268.00 to the University of New Mexico Health Sciences Center (UNM HSC) to support research on the role of mitochondrial acid-sensing ion channel 1 in pulmonary hypertension. The award period is from February 3, 2025 to February 28, 2025. As a major public research university and comprehensive academic medical center, UNM HSC...
The federal Project Grant award R01HL176673, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to determine the molecular mechanisms by which the protein factor Response Gene to Complement 32 (RGC-32) regulates endothelial-mesenchymal transition (EndoMT) of pulmonary artery endothelial cells and its role in the development of pulmonary arterial hypertension (PAH). The $658,885 award, with a...